| Autor: |
Barysheva EV; Institutes of Cardiology and Oncology, Tomsk Medical Research Center., Obradovic V, Stefanovic L, Riannel' IuE, Regoe S, Selivanov SP, Artiko V, Isaeva SN, Velichko SA, Tuzikov SA, Ussov VIu |
| Jazyk: |
ruština |
| Zdroj: |
Vestnik rentgenologii i radiologii [Vestn Rentgenol Radiol] 2000 Nov-Dec (6), pp. 46-50. |
| Abstrakt: |
We evaluated possibilities of bone scintigraphy with 99mTc-methylendiphosphonate (99mTc-MDP) and magnetic resonance imaging (MRI) in follow-up and prediction of effect in patients with extensive bone metastatic disease treated with betha-emitter 89SrCl2. 24 patients with prostate cancer and extensive metastatic involvement of skeleton were referred for the study. 89SrCl2 was injected as single injection of 150 MBq (4 mCi), in eighteen from Amersham plc., England, as Metastron, in six--from Medradiopreparat, Russia). In all patients bone scintigraphy with 99mTc-MDP and MRI study of metastatic regions were performed before and in 3 months after 89SrCl2 injection. Patients treated with Metsatron were also studied in 6 months after injection. Quantitative analysis of data comprised count and anatomic dimensions of metastatic areas and calculation of indices [metastasis/intact bone] both for scintillation count of 99mTc-MDP bone scans and signal intensity of T1-weighted MRI scan. Henceforth, we conclude the data of bone scanning with 99mTc-MDP and of MRI give evidencies for significant regress of bone metastases in patients treated with 89SrCl2 besides symptomatic suppression of pain syndrome. 99mTc-MDP bone scanning is also of predictive value for the prognosis of therapeutic effect of systemic radiotherapy with 89SrCl2 in prostate cancer. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
